The company submitted the marketing authorization application (MAA) under the European Medicines Agency’s exceptional circumstances approval rules for breakthrough therapies for rare diseases such as Li-Fraumeni Syndrome (LFS).
This patent expands the company’s existing US and international IP portfolio to 22 issued patents and 30 pending patents. It also provides further protection for the company’s growing
In the trial, eight patients with routine high cholesterol on stable doses of less than or equal to 40mg/day of statins were treated with 200mg/week mipomersen for three
The double-blind, randomized trial is expected to enroll up to 387 patients to be completed over a period of 24 months. Patients will be randomized on a two
This research study is a double-blind, placebo-controlled randomized Phase IIb study that will be conducted at about 50 sites in approximately 20 states. In addition to evaluating the
The contract will be retroactive to November 1, 2007 and will cover the Health Alliance’s University Hospital, Jewish Hospital, Fort Hamilton Hospital, Drake Center, the 200 physicians of
ImmunoCellular (IMUC) has also announced that it has filed with the US patent office the two principal applications covering its multiple antigen dendritic cell cancer vaccine and cancer
The Phase IIb study is a placebo-controlled, parallel-group, double-blind randomized 12-week study in 172 patients. The study contains four arms with 43 patients per arm. KB2115 will be
Under terms of the agreement, Applied Biosystems retains the rights to commercialize all genotyping applications, including assays other than ones based on TaqMan technology, for BioTrove’s platform. Applied
Under the agreement, the National Cancer Institute (NCI) will supply Agencourt with normal and cancer tumor tissue samples and periodic lists of genes and targeted regions to be
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.